530 reports of this reaction
2.0% of all RALOXIFENE HYDROCHLORIDE reports
#11 most reported adverse reaction
BODY HEIGHT DECREASED is the #11 most commonly reported adverse reaction for RALOXIFENE HYDROCHLORIDE, manufactured by Eli Lilly and Company. There are 530 FDA adverse event reports linking RALOXIFENE HYDROCHLORIDE to BODY HEIGHT DECREASED. This represents approximately 2.0% of all 26,004 adverse event reports for this drug.
Patients taking RALOXIFENE HYDROCHLORIDE who experience body height decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BODY HEIGHT DECREASED is a less commonly reported adverse event for RALOXIFENE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to body height decreased, the following adverse reactions have been reported for RALOXIFENE HYDROCHLORIDE:
BODY HEIGHT DECREASED has been reported as an adverse event in 530 FDA reports for RALOXIFENE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BODY HEIGHT DECREASED accounts for approximately 2.0% of all adverse event reports for RALOXIFENE HYDROCHLORIDE, making it a notable side effect.
If you experience body height decreased while taking RALOXIFENE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.